ClinicalTrials.gg
CompletedNCT05447546Updated Aug 28, 2023

Study to Evaluate HT-6184 in Healthy Subjects

A Phase 1 interventional study of HT-6184 and HT-6184 Placebo in Normal Healthy Subjects, sponsored by Halia Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-28.

Sponsored by Halia Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The primary objectives of this study are to evaluate the safety and tolerability of HT-6184 when administered as single oral doses at escalating dose levels in healthy volunteer subjects.

The secondary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of HT-6184. Results of the PD analyses will be used to determine the minimal biologically effective dose (MBED): the lowest dose that achieves >70% target inhibition compared to unstimulated vehicle controls over 24 hours in 4 of 6 treated volunteers.

Read the detailed description

This is a phase 1, randomized, placebo-controlled, single-center, single and multiple ascending dose study designed to evaluate the safety, tolerability, PK, and PD of HT-6184.

Each cohort in the study will be comprised of 8 subjects, 6 subjects will receive HT-6184 and 2 subjects will receive placebo. A dose range of 1 mg - 4 mg HT-6184 will be explored in the SAD and MAD escalation cohorts in adult healthy volunteer subjects. Safety and PK data from the 8 completed cohorts will be reviewed.

For the SAD portion subjects will be divided into 4 cohorts of 8 subjects in each cohort. Four (4) ascending single doses (1 dose level per cohort) will be investigated.

Subjects will be screened for eligibility to participate in the study up to 26 days (Day -28) prior to admission to the study center on Day -2. Eligible subjects will be admitted to the study center on Day -2 and will be discharged on Day 2 after all scheduled assessments have been completed. Following discharge, subjects will return to the study center for follow-up visits on Day 7 and receive a follow-up phone call on Day 30.

A modified Fibonacci escalation schedule starting at 1 mg, (escalating by 100%) 2 mg, (escalating by 50%) 3 mg, and (escalating by 33%) 4 mg. The study will have an ongoing assessment of all available safety, tolerability, and concentration data prior to initiation of the next cohort.

For the MAD portion subjects will be divided into 4 cohorts of 8 subjects in each cohort. Four (4) ascending multiple doses (1 dose level per cohort) will be investigated.

Subjects will be screened for eligibility to participate in the study up to 26 days (Day -28) prior to admission to the study center on Day -2. Eligible subjects will be admitted to the study center on Day -2 and will be discharged on Day 13 after all scheduled assessments have been completed. Following discharge, subjects will return to the study center for a follow-up visit on Day 21 and receive a follow-up phone call on Day 42.

02

Conditions studied

  • Normal Healthy Subjects
03

In context

Lead sponsor

Halia Therapeutics, Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is male or female, between 18 and 65 years of age (inclusive) at Screening;
  2. Has a (BMI) between 18.0 and 32.0 kg/m2 (inclusive) at Screening
  3. Is in good general health, as determined by the Investigator, without medical history;
  4. Normal physical examination, 12-lead (ECG), and vital signs, as determined by the Investigator;
  5. Clinical laboratory values within the normal limits as defined by the clinical laboratory reference range;
  6. Female partners of male participants of , and female participants of childbearing potential must agree to use a highly effective method of prior to study entry, for the duration of study participation, and a minimum of 30 days after the last dose. Highly effective forms of contraception include the following:

    • Established use (i.e., at least 30 days prior to enrollment) of combined (estrogen and progestogen containing) oral, intravaginal or transdermal hormonal contraception associated with inhibition of ovulation,
    • Established use (i.e., at least 30 days prior to enrollment) progestogen-only oral, injectable or implantable hormonal contraception associated with inhibition of ovulation,
    • Established use (i.e., at least 30 days prior to enrollment) of an intrauterine device (IUD) or intrauterine hormone-releasing system (IUS),
    • bilateral tubal occlusion,
    • vasectomized partner, provided that partner is the sole sexual partner of the female trial participant and that the vasectomized partner has received medical assessment of the surgical success,
    • sexual abstinence, defined as refraining from heterosexual intercourse during the study, when this is in line with the preferred and usual lifestyle of the subject.
  7. In the case of a female of childbearing potential, has a negative serum pregnancy test (SPT) at Screening and Day -2 and is willing to submit to a SPT at the end of study (EOS);
  8. Negative urine test for drugs of abuse and breath test for alcohol use at Screening and check-in (Day -2). The tests may be repeated once if necessary and deemed appropriate by the Investigator;
  9. Agree to refrain from tobacco or nicotine containing products within 48 hours prior to Day 1 and during the periods when PK blood samples are collected;
  10. Agree to refrain from alcohol consumption within 48 hours prior to Day 1 and during the periods when PK blood samples are collected;
  11. Agree to refrain from caffeine (i.e., coffee, tea, caffeinated soda, chocolate) within 48 hours prior to Day 1 and during the periods when PK blood samples are collected;
  12. Agree to refrain from grapefruit, Seville oranges, and pomelo containing products within 72 hours prior to Day 1 and during the periods when PK blood samples are collected; and
  13. Read, understand, and sign an .

Exclusion criteria

Exclusion Criteria:

  1. A female who is pregnant, plans to become pregnant during the study, or is breastfeeding a child;
  2. Any central nervous system, cardiac, pulmonary, renal, gastrointestinal (GI), endocrinological, respiratory, or metabolic conditions (or history), or other pathological or physiological conditions, that might interfere with the study results in the investigator's opinion;
  3. Any condition which, in the investigator's opinion, puts the participant at significant risk, could confound the study results, or may interfere significantly with the subject's participation in the study;
  4. Immunization within 10 days of Day 1;
  5. Anticipated need for surgery or hospitalization during the study;
  6. Consumed alcohol within 48 hours prior to Day 1 or refuses to abstain from alcohol throughout the duration of the study;
  7. History of heavy smoking (i.e., more than 10 cigarettes a day or the tobacco/nicotine equivalent) within 3 months of screening or refuses to abstain from tobacco or nicotine-containing products throughout the duration of the study;
  8. Donation or loss of blood (excluding volume drawn at screening) of ≥ 450 mL within 3 months of Day 1;
  9. Active or lifetime infection (e.g., negative test for (HIV) and hepatitis, and no history of tuberculosis and syphilis) or a history of severe infection during the 30 days prior to screening;
  10. Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment;
  11. Prior treatment with a NLRP3 inhibitor for any indication;
  12. Is unwilling or unable to refrain from using prescription medications for 30 days prior to Day 1 or over the counter medications, herbal preparations, and supplements for 14 days prior to Day 1 (excluding permitted forms of and occasional use of acetaminophen [up to 2 g in 24 hours]);
  13. Inability or unlikeliness of the participant to comply with the dose schedule and study evaluations, in the opinion of the investigator;
  14. Is currently participating in any clinical trial;
  15. Has received any drug(s) within 30 days or 5 half-lives, whichever is longer, prior to study Day 1;
  16. Any condition that would, in the investigator's judgment, interfere with full participation in the study, including attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data; and/or
  17. Inability of the participant (or legally authorized representative) to comprehend the form (ICF) or unwillingness to sign the ICF.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
64 participants (actual)

Study arms

  • Active comparator
    1 mg HT-6184 QD

    Cohort 1 - 6 subjects x 1 mg HT-6184 QD on Day 1

    Drug: HT-6184

  • Placebo comparator
    1 mg Placebo QD

    Cohort 1 - 2 subjects x placebo, QD on Day 1

    Drug: HT-6184 Placebo

  • Active comparator
    2 mg HT-6184 QD

    Cohort 2 - 6 subjects x 2 mg HT-6184 QD on Day 1

    Drug: HT-6184

  • Placebo comparator
    2 mg Placebo QD

    Cohort 2 - 2 subjects x placebo, QD on Day 1

    Drug: HT-6184 Placebo

  • Active comparator
    3 mg HT-6184 QD

    Cohort 3 - 6 subjects x 3 mg HT-6184 QD on Day 1

    Drug: HT-6184

  • Placebo comparator
    3 mg Placebo QD

    Cohort 3 - 2 subjects x placebo, QD on Day 1

    Drug: HT-6184 Placebo

  • Active comparator
    4 mg HT-6184 QD

    Cohort 4 - 6 subjects x 4 mg HT-6184 QD on Day 1

    Drug: HT-6184

  • Placebo comparator
    4 mg Placebo QD

    Cohort 4 - 2 subjects x placebo, QD on Day 1

    Drug: HT-6184 Placebo

  • Active comparator
    1 mg HT-6184 QD x 2 weeks

    Cohort 5 - 6 subjects x 1 mg HT-6184 QD on Day 1-5, 8-12

    Drug: HT-6184

  • Placebo comparator
    1 mg Placebo QD x 2 weeks

    Cohort 5 - 2 subjects x 1 mg placebo, QD on Day 1-5, 8-12

    Drug: HT-6184 Placebo

  • Active comparator
    2 mg HT-6184 QD x 2 weeks

    Cohort 6 - 6 subjects x 2 mg HT-6184 QD on Day 1-5, 8-12

    Drug: HT-6184

  • Placebo comparator
    2 mg Placebo QD x 2 weeks

    Cohort 6 - 2 subjects x 2 mg placebo, QD on Day 1-5, 8-12

    Drug: HT-6184 Placebo

  • Active comparator
    3 mg HT-6184 QD x 2 weeks

    Cohort 7 - 6 subjects x 3 mg HT-6184 QD on Day 1-5, 8-12

    Drug: HT-6184

  • Placebo comparator
    3 mg Placebo QD x 2 weeks

    Cohort 7 - 2 subjects x 3 mg placebo, QD on Day 1-5, 8-12

    Drug: HT-6184 Placebo

  • Active comparator
    4 mg HT-6184 QD x 2 weeks

    Cohort 8 - 6 subjects x 4 mg HT-6184 QD on Day 1-5, 8-12

    Drug: HT-6184

  • Placebo comparator
    4 mg Placebo QD x 2 weeks

    Cohort 8 - 2 subjects x 4 mg placebo, QD on Day 1-5, 8-12

    Drug: HT-6184 Placebo

Interventions

  • Oral capsule

  • DrugHT-6184 Placebo

    Oral capsule

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events administered as single oral doses at escalating dose levels in healthy volunteer subjects.

    Safety and tolerability of HT-6184 as measured by subject incidence of treatment-related adverse events.

    Time frame: up to 6 weeks

  2. Incidence of abnormal laboratory test results

    Safety and tolerability of HT-6184 as measured by subject incidence of treatment-related abnormal lab values.

    Time frame: up to 6 weeks

  3. Incidence of treatment-emergent clinically abnormal electrocardiogram (ECG)

    Safety and tolerability of HT-6184 as measured by subject incidence of treatment-related abnormal ECG.

    Time frame: up to 6 weeks

  4. Incidence of treatment-emergent clinically abnormal physical exam

    Safety and tolerability of HT-6184 as measured by subject incidence of treatment-related abnormal physical exam.

    Time frame: up to 6 weeks

Secondary outcomes

  1. Plasma maximum measured drug concentration (Cmax)

    Cmax will be reported.

    Time frame: up to 6 weeks

  2. Time of maximum concentration (Tmax)

    Tmax will be reported.

    Time frame: up to 6 weeks

  3. Area under the plasma concentration-time curve (AUC0-24)

    Area under the plasma concentration-time curve from 0 until 24 hours post-dose will be reported.

    Time frame: up to 6 weeks

  4. Area under the plasma concentration-time curve (AUC0-last)

    Area under the plasma concentration-time curve, from 0 to the last quantifiable timepoint will be reported.

    Time frame: up to 6 weeks

  5. Area under the plasma concentration-time curve (AUC0-inf)

    Area under the plasma concentration-time curve, from 0 to infinity will be reported.

    Time frame: up to 6 weeks

  6. Plasma half-life (T½)

    T½ will be reported.

    Time frame: up to 6 weeks

  7. Terminal elimination rate constant (kel)

    Terminal elimination rate constant will be reported.

    Time frame: up to 6 weeks

  8. Apparent clearance (CL/F)

    CL/F will be reported.

    Time frame: up to 6 weeks

  9. Apparent volume of distribution at steady state (Vss/F)

    Vss/F will be reported.

    Time frame: up to 6 weeks

07

Study locations

1 site
  • TKL Research, Inc.
    Fair Lawn, New Jersey 07410, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Jul 2023, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2022
First posted
Jul 7, 2022
StartActual
Jun 15, 2022
Primary completionActual
Jul 20, 2023
CompletionActual
Jul 20, 2023
Last update
Aug 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05447546
Lead sponsor
Halia Therapeutics, Inc.
Collaborators
TKL Research, Inc.
Responsible party
Sponsor
First posted
Jul 7, 2022
Start date
Jun 15, 2022
Primary completion
Jul 20, 2023
Completion
Jul 20, 2023
Last update
Aug 28, 2023

Study contacts

Jesson Yeh, MD
principal investigator · TKL Research, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ofirnoflast

Start the discussion